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Abstract: The intensive care units (ICUs) are burdened with a high frequency of nosocomial infections often caused by multiresistant
nosocomial pathogens. Pseudomonas aeruginosa has emerged as one of the most problematic Gram-negative pathogens. The
objective of this study was to identify frequency of Pseudomonas aeruginosa from the various clinical samples in ICUs, and to
investigate resistance patterns against various antibiotics widely used for treatment. This study was carried out between September
2000-September 2002. Antimicrobial susceptibility testing was performed by the disc diffusion method according to NCCLS
(National Commitee for Clinical and Laboratory Standards) guidelines. The following antibiotics were tested: imipenem, meropenem,
aztreonam, ciprofloxacin, ceftazidime, cefepime, piperacillin, norfloxacin and the aminoglycosides (gentamicin, netilmicin,
tobramycin, and amikacin). Pseudomonas aeruginosa were isolated from 16.4 % (152/928) of the patients in ICUs. The highest
Pseudomonas aeruginosa isolation was obtained in the burns unit (26.9%, 78/290) followed by, cardiovascular surgical ICU (17.6%,
13/74) general surgical ICU (24/164, 14.6 %), internal ICU (17/180, 9.4%) and coronary ICU (20/220, 9.1%). There is a
statististically significant difference between surgical ICU and medical internal ICU (P < 0.05). The most effective antibiotics were
carbapenems (imipenem and meropenem) and the resistance rates were detected as 15% and 20.4%, respectively among 152
Pseudomonas aeruginosa strains.
In conclusion, the frequency of Pseudomonas aeruginosa was found to be high in patients treated at ICUs. The results demonstrate
that the resistance rates are alarmingly high. To reduce the emergence and spread of antimicrobial-resistant pathogens in ICUs,
monitoring and optimisation of antimicrobial use should be considered carefully. These findings suggest that the resistance rates of
aminoglycosides, 3th generation antibiotics and quinolone are increasing progressively in Turkey.
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Introduction

Pseudomonas aeruginosa, the primary human
pathogen in the genus Pseudomonas, is widely distributed
in nature. It may colonize healthy humans without
causing diseases, but is also a significant opportunistic
pathogen, and a major cause of nosocomial (hospitalacquired) infections. Pseudomonas aeruginosa is regularly
a cause of nosocomial pneumonia, nosocomial urinary
tract infections, surgical site infections, infections of
severe burns, and infections patients undergoing either
chemotherapy for neoplastic diseases or antibiotic
therapy (1,2).

Pseudomonas aeruginosa is one of the most common
nosocomial pathogens in humans and is often a major
problem. Though rare in the normal flora of humans, it is
isolated frequently from hospitalized patients.
Pseudomonas aeruginosa is one of the most important
microorganisms which causes problems clinically as a
result of its high resistance to antimicrobial agents1. The
widespread occurrence of antibiotic resistant strains of
Pseudomonas aeruginosa in hospitals is a matter of
growing concern. Unfortunately, there are no specific
measures to prevent nosocomial pseudomonal infections.
Despite the availability of a variety of effective
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antimicrobial agents, treatment of
pneumonia is often challenging (3,4).

pseudomonal

Pseudomonas aeruginosa remains an important cause
of hospital-acquired infections especially in intensive care
units (ICUs). The diversity of clinics and the regional
variations in antibiotic protocols result in the different
resistance profiles (2,3,4).
Patients hospitalised in ICUs are at particular risk of
acquiring nosocomial infections due to serious underlying
disease, compromised membrane and skin barriers
following the use of invasive devices, and extended length
of hospital stay, among other factors. Exposure to
various antimicrobial agents may further complicate such
hospitalisation and create conditions conducive to
resistance selection among host bacterial flora or
nosocomially-transmitted pathogens. Studies have
demonstrated that rates of antimicrobial resistance are
greater in bacteria isolated from ICUs compared with
other hospital wards and outpatient clinics (5).
Antimicrobial resistance is a growing problem
worldwide, especially in hospitals, where resistant
organisms are often first detected in ICUs. Pseudomonas
aeruginosa frequently displays resistance to multiple
antimicrobial agents (6). Serious infection due to strains
of Pseudomonas aeruginosa that exhibit resistance to all
common antipseudomonal antimicrobials is an
increasingly serious problem (7).
In this study we aimed to establish the prevalence of
Pseudomonas aeruginosa in the ICUs of our hospital and
to compare their antibiotic susceptibility patterns.

Materials and Methods
This study was conducted in the ICUs and burns unit
of a teaching hospital over a period of 24 months. The
study was undertaken to find the prevalence of hospitalacquired Pseudomonas aeruginosa infection in Baskent
University Hospital in Adana, Turkey between September
2000- September 2002. In this study, 152 Pseudomonas
aeruginosa were isolated from 928 patients hospitalized
in four different ICU (coronary ICU, surgical ICU, internal
ICU, cardio vascular surgical ICU) and burns unit.

Pseudomonas aeruginosa were identified by colonial
morphology, a positive oxidase reaction, pyocyanin
production on Mueller-Hinton agar (Difco), motility and
growth at 42 ºC on cetrimide agar. Colonies which
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displayed a positive oxidase reaction were subcultured,
and characterised using a commercial biochemical
identification kit (API NE). One sample was studied from
each patient. The sensitivity of Pseudomonas aeruginosa
strains to imipenem (10 mg/disc), meropenem (10
mg/disc), aztreonam (30 mg/disc), ciprofloxacin (5
mg/disc), ceftazidime (30 mg/disc), netilmicin (30
mg/disc), cefepime (30 mg/disc), gentamicin (10
mg/disc), tobramycin (10 mg/disc), amikacin (30
mg/disc), piperacillin (100 mg/disc) and norfloxacin (10
mg/disc) was investigated by the Kirby-Bauer disc
diffusion method according to NCCLS (National Commitee
for Clinical and Laboratory Standards) criteria (8).
Mueller-Hinton broth was used as the growth medium.
The final bacterial inoculum concentration was
8
approximately 1.5x10 colony-forming units/ml (cfu/ml).
Before the antibiotic discs were placed, the MuellerHinton plates were inoculated with swabs submerged in
the final inoculum concentration and streaked over the
entire surface of the plates. Plates were incubated
aerobically at 35-37 ºC for 18-24 hours. All antibiotic
discs were obtained from Oxoid.
As a control strain, ATCC 27853 was used for
identification and susceptibility tests.
Statistical analysis
Statistical analysis was performed using a chi square
test and P values less than 0.05 were considered
statistically significant. The statistical analyses were
performed using Statistical Package for Social Sciences
(SPSS, ver 10.0) software.

Results
Over a period of twelve months (between Semtember
2000-Semtember 2002), a total of 152 Pseudomonas
aeruginosa strains were isolated from hospitalized
patients in different ICUs and burns unit. The highest
isolation rates of Pseudomonas aeruginosa strains were
observed among the following departments in descending
order: burns unit (26.9%), cardiovascular surgical ICU
(17.6%), surgical ICU (14.68%), medical internal ICU
(9.4%), and coronary ICU (9.1%) (Figure 1). There was
no difference in isolation rate between medical internal
ICU and coronary ICU (P > 0.05), but there was a higher
isolation rate in burns unit than the others ICUs (P <
0.05). The same important difference was detected
between surgical ICUs (cardiovascular surgical ICU,
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Figure 1. Isolation rates Pseudomonas aeruginosa according to departments.

surgical ICU) and medical internal ICUs (medical internal
ICU, coronary ICU), (P < 0.05).
In this study, Pseudomonas aeruginosa was isolated
from 152 out of 928 patients (16.4%) from whom
various clinical samples (such as, urinary, surgical site
infections, burns, tracheal aspiration samples) were
taken.
The antibiotic resistance patterns of isolates are
presented in Figure 2. The most effective antibiotics were
carbapenems (imipenem and meropenem) and the
resistance rates were detected as 15% and 20.4%,
respectively among 152 Pseudomonas aeruginosa strains.
Against norfloxacin, ciprofloxacin, and piperacillin
however, resistance rates of Pseudomonas aeruginosa
strains were 25.5%, 27.4% and 28.7, respectively.
Apart from these antibiotics, the most effective
antibiotics were netilmicin (30.1%), cefepime (39.0%),
amikacin (42.2%), cefotaxime (48.9%), aztreonam
(63.1%), tobramycin (65.5%) and gentamicin (70.7)%.

Discussion

Pseudomonas aeruginosa is a major cause of
nosocomial infection. Despite advances in sanitation
facilities and the introduction of a wide variety of
antimicrobial agents with antipseudomonal activities, lifethreatening infections caused by Pseudomonas
aeruginosa continue to be hospital infections. ICU patients
are particularly susceptible to nosocomial infection
because the normal skin and mucosal barriers to infection
are commonly compromised by the use of invasive devices
(9). The distribution of isolates is significantly affected by

the type of hospital (general, teaching or specialized). It
is reported that isolation due to nosocomial infection
changes from 3% to 16% in multi-center studies.
Pseudomonas aeruginosa is the most common pathogen
in nosocomial infections. It is the leading cause of
nosocomial respiratory tract infections (2,3,10).
Intensive care patients especially create an
environment for infection because of the debilitating
effect of a prolonged hospitalisation and the application
of medical equipment (airways, catheters etc) (10).
In this study, the highest Pseudomonas aeruginosa
isolation rate (26.9%) was obtained in the burns unit
which was followed by cardiovascular surgical ICU
(17.6%), surgical ICU (14.68%), medical internal ICU
(9.4%), and coronary ICU (9.1%). There was a
statististically significant difference between surgical ICUs
and medical internal ICUs (P < 0.05, Figure 1). The burns
units are a very susceptible habitat for bacterial
colonization (11). ICUs are generally considered
epicenters of antibiotic resistance and the principal
sources of outbreaks of multi-resistant bacteria. The
most important risk factors are obvious, such as excessive
consumption of antibiotics exerting selective pressure on
bacteria, the frequent use of invasive devices and relative
density of a susceptible patient population with severe
underlying diseases (12).
Nowadays, the prevalence of Pseudomonas
aeruginosa and the new resistant strains continue in both
community-acquired pathogens and hospital originated
infections (13).
In a study carried out in Turkey, Inan et al. isolated
68% of Pseudomonas aeruginosa strains and 60-83% of
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Figure 2. Resistance rates of Pseudomonas aeruginosa.

the antibiotics resistant strains from ICU patients. In the
same study, resistance was detected against ceftazidime
34%, imipenem 26%, gentamicin 67%, and amikacin
26% (14).
Recently, increased resistance has been observed
against 3th generation cephalosporins for gram negative
bacilli, especially Pseudomanas aeruginosa (16).
Cefepimee and Ceftazidime are the commonest 3th
generation antibiotics in ICU protocols. Ceftazidime has a
key role in resistance detection in ICUs. However in ICUs,
antibiotic therapy protocols are different in almost all
countries and there are also regional differences (15).
Resistance to Cefepimee and Ceftazidime are significant
in our study (30.1-48.9%). Previous studies suggest that
the selective pressure from the use of antimicrobial
agents is a major determinant for the emergence of
resistant strains (9,12,15).
One of the significant resistant groups detected
against aminoglycosides was Pseudomanas aeruginosa
(17). Resistance of gram-negative aerobic bacteria to
aminoglycoside antibiotics differs according to region and
country. Resistance to aminoglycosides was higher in
Southern Europe than in Central and Northern Europe
(17). Reports of the susceptibility of Pseudomanas
aeruginosa to gentamicin and tobramycin have ranged
from as low as 49.8% and 77.7%, in Greece, to as high
as 96.6% and 99.2%, respectively, in the United
Kingdom (17). Previous studies reported that
antipseudomonal effects of amikacin were greater than
those of gentamicin (18,19). In the present study, the
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rate of aminoglycoside resistance was found to be
relatively high (resistance to amikacin; 42.2%, netilmicin;
30.1%, tobramycin; 65.5% and gentamicin; 70.7%).
However, in 1988, it was reported that 54% of gramnegative bacilli in Turkey were resistant to gentamicin,
35% to tobramycin, and only 0.9% to amikacin (18).
Consistent with these findings, resistance to amikacin of
Pseudomanas aeruginosa was still lower than to
tobramycin or gentamicin. However, this data suggests
that resistance to amikacin is increasing progressively in
our country.
In various studies, it was reported that increased
resistance rates have been detected against to
carbapenems,
quinolons
and
third-generationcephalosporins for Pseudomanas aeruginosa worldwide
(20-22). In our study, resistance rates against imipenem
and morenepem from carbanemem groups were
determined as 15% and 20%, respectively.
Additionally, in our study presented here, the
resistance rate was found as 28% against piperaciline
from ureipenicillin group, and 63% for monobactam
from aztreonam group.
In the literature, it was reported that resistance to
imipenem was 14% in Spain (23), 19.3% in Italy (24),
and 68% in Saudi Arabia (25). The National Nosocomial
Infections Surveillance (NNIS) system reported the
incidence of imipenem resistance as 18.5% among
isolates of Pseudomanas aeruginosa from ICU patients
(26).

L. SAVAfi , N. DURAN, N. SAVAfi, Y. ÖNLEN, S. OCAK

The Meropenem Yearly Susceptibility Test
Information Collection (MYSTIC) study group reported an
incidence of 19% in 10 medical centres (27). In a later
study, it was reported that Pseudomonas aeruginosa
strains have developed relatively high resistance levels
against to quinolone group (28).
The resistance of Pseudomonas to the antibiotics in
the quinolone group is variable in different centers
(28,29). In a prospective study, resistance to
ciprofloxacin in ICU was reported as 8-31% (30). In this
study, resistance rates against ciprofloxacin and
norfloxacin were found as 27.4%, 25.5%, respectively.
Quinolone resistance in our study is the same as these
reports.
Ciprofloxacin resistance rate was 23% in Spain (23),
31.9% in Italy (24), and 26.8% in Latin America (31).
Contrary to ciprofloxacin, our isolates were highly
resistant to ceftazidime (48.9%). According to different
reports, resistance to ceftazidime was 15%-22% in the
world (23,24,31). Resistance to piperacillin was higher,
similar to ceftazidime. While piperacillin resistance rate
was 10% in Spain (23), 12% in Italy (24), 14% in Latin
America (31), it was found as 28.7 in our study.
Resistance rates of anti-pseudomonal antibiotics were
quite low in the United Kingdom: 5% for ceftazidime, 7%
for piperacillin, 10% for ciprofloxacin, and 11% for
imipenem (32).

As a result, the resistance to antipseudomonal
antibiotics was found to be higher than in the previous
studies reported in different countries in the isolated
Pseudomanas aeruginosa strains from ICU patients in our
hospital (5,10,12,24,25,28).
Thus, in ICUs, empirical antibiotic treatments should
be avoided and treatment should be carried out using
antibiotic susceptibility tests. ICUs should be regularly
inspected for Pseudomonas colonization which shows a
strong resistance pattern against the various antibiotics.
Colonization of ICU patients with antimicrobial-resistant
pathogens can lead to clinical infection because of
breakdown of normal host defenses.
In conclusion, we recommend regular screening of
ICU patients to give an early warning of the presence of
antimicrobial-resistant pathogens and allow the
assessment of barrier and infection control techniques.
Such monitoring can also aid infection control in
determining how to focus efforts an reducing the
emergence and spread of antimicrobial resistant
pathogens.
Corresponding author:
Department of Microbiology,
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